Orphan Designated Drugs – Strategic Intelligence

Orphan Designated Drugs Strategic Intelligence Report Overview

Due to the unmet medical demands of many rare diseases around the world, the number of orphan designated drugs (ODD) by regulatory agencies such as the FDA and EMA has increased in recent years. This has arisen from international recognition of the significant number of people that rare diseases affect daily, paired with limited therapeutic options and low patient populations. As a result, a wide variety of pharmaceutical companies are expanding their orphan drug portfolio through co-development partnerships and collaborations, innovative means of personalized and precision therapy, as well as receiving financial and legal support from regulatory bodies to meet this unmet medical need.

The orphan designated drugs strategic intelligence trends report gives you an in-depth insight into the value chain. It further entails a deep-dive analysis of the industry, including key market trends that will shape the theme over the coming years, as well as market values for the current and forecast periods. The orphan designated drugs strategic intelligence trends report gives an insight into the market players and the competitive landscape within the theme.

Orphan Designated Drugs – Key Trends

The main trends shaping the ODD theme over the next 12 to 24 months are classified into healthcare, technology, macroeconomic, and regulatory trends.

• Healthcare trends: Genomics, cell and gene therapy, dominance in oncology, diagnostics and biomarkers, and decentralized clinical trials are among the healthcare trends impacting the theme.
• Technology trends: The key technology trends impacting the ODD theme are AI and big data, cloud computing, cybersecurity, and three-dimensional (3D) printing.
• Macroeconomic trends: The rising popularity of orphan drugs and drug pricing, market growth of ODD, merger and acquisition (M&A) activity, and social inclusion and diversity are among the points to be considered for macroeconomic trends.
• Regulatory trends: Reimbursement landscape and data privacy are the regulatory trends impacting the theme.

Buy the Full Report for More Trend Insights into the Orphan Designated Drugs Theme

Download a Free Report Sample

Orphan Designated Drugs Value Chain Analysis

The orphan designated drugs value chain is split into drug discovery and development, clinical trials, and others.

Drug discovery and development: The implementation of drug discovery and development is an essential factor within the value chain for therapeutics that undergo ODD. Such designations are often approved for rare diseases with limited patient populations and thus face difficult barriers to entry paired with high unmet medical demands within the pharmaceutical landscape. As a result, researchers begin their initial endeavors in discovering personalized therapeutic targets, seeking ODD approval, and initiating pre-clinical feasibility studies.

Orphan Designated Drugs Value Chain Analysis

Buy the Full Report for More Insights into the ODD Value Chain
Download a Free Report Sample

Orphan Designated Drugs – Competitive Landscape

The key companies that will make their mark within the ODD theme are as follows:

Public Companies: A few of the leading listed players associated with this theme are AbbVie, Amgen, and Argenx, among others.

Private Companies: A few of the interesting private companies associated with this theme are Abzena, Axplora Group, and Mitsubishi Tanabe Pharma America, among others.

Key Companies in ODD Theme

Buy the Full Report to Know More about the Orphan Designated Drugs Theme
Download a Free Report Sample

Clinical Trial Sector Scorecard

At GlobalData, we use a scorecard approach to predict tomorrow’s leading companies within each sector. Our sector scorecard has three screens: a thematic screen, a valuation screen, and a risk screen.

• The thematic screen ranks companies based on overall leadership in the 10 themes that matter most to their industry, generating a leading indicator of future performance.
• Our valuation screen ranks our universe of companies within a sector based on selected valuation metrics.
• Our risk screen ranks companies within a particular sector based on overall investment risk.

Clinical Trial Sector Scorecard – Thematic Screen

Buy the Full Report to Know More about the Sector Scorecards in the ODD Theme
Download a Free Report Sample

Scope

• It is a dedicated report examining the pivotal healthcare, technological, macroeconomic, and regulatory trends shaping the orphan designated drugs field in the pharma landscape.
• This report also provides an in-depth analysis of how these trends are poised to either accelerate progress or create obstacles for the growth of the orphan designated drugs market.

Key Highlights

This report consolidates GlobalData’s latest thinking and forecasts around how the healthcare, macroeconomic, technology, and regulatory trends will impact the orphan designated drugs in pharma space, as well as providing insights into the leading players and future challengers across the value chain, and providing insights into key drugs and markets from GlobalData’s Pharma Intelligence Center. Additionally, this report is designed to provide strategic planners, competitive intelligence professionals and key stakeholders in the pharmaceutical industry a clear view of the opportunities and risks over the foreseeable future.

Reasons to Buy

Understand the key trends accelerating or hindering the orphan designated drugs in the pharma space.